|Study Description:||Why is this study being done?|
Moxetumomab pasudotox is an investigational agent that was developed to target
a particular molecule, CD22, that can be found on the surface of cancer cells
and to selectively kill the cells that have the molecule. Moxetumomab
pasudotox has not been approved by the Food and Drug Administration (FDA).
Overall about 155 patients, both children and adults, have been treated with
moxetumomab pasudotox with limited side effects which are discussed in the
risks section of the consent.
We hope this study will show that moxetumomab pasudotox can work in humans to
kill cancer cells especially those cells that have CD22 on their surface.